The ethics and management of cannabis use in pregnancy following decriminalisation and licensing for medical use: narrative review

Abdulazeed Towobola,¹ Basirat Towobola,² Bosky Nair,³ Arti Makwana⁴

BJPsych Bulletin (2023) 47, 28–37, doi:10.1192/bjb.2021.102

¹Kent and Medway NHS and Social Care Partnership Trust, Maidstone, Kent, UK; ²East Sussex Healthcare NHS

Trust, Hastings, East Sussex, UK; ³Kent and Medway NHS and Social Care Partnership Trust, Maidstone, Kent, UK;

⁴Kent and Medway NHS and Social Care Partnership Trust, Maidstone, Kent, UK

Correspondence to Dr Abdulazeed Towobola (a.towobola@nhs.net)

First received 17 Jan 2021, final revision 14 Sep 2021, accepted 8 Oct 2021

© The Author(s), 2021. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aims and method As drug policies pertaining to cannabis use become more liberalised, the prevalence of cannabis use in pregnancy could increase. However, there is limited guidance available for clinicians. This paper presents a narrative review of literature published in the past 16 years (2006–2021) to (a) address the impact of legalisation and decriminalisation on the risks, ethics and support of women who use cannabis during pregnancy and (b) develop guidance for clinicians.

Results Both national and international trends suggest increased use of cannabis over the past decade, while the risks of cannabis use for recreational or medicinal purposes in pregnancy remain unmitigated.

Clinical implications This review confirmed that the recommendation of cannabinoid-based products for pregnant and breast-feeding women is currently premature. More research is needed to address safety concerns. We discussed navigating ethical concerns and suggest targeted management strategies for clinicians treating pregnant women who choose to use cannabis.

Keywords Cannabis; pregnancy; risk; ethics; decriminalisation

The Crime Survey of England and Wales¹ showed that in 2019 the most common drugs taken by adults aged 16–59 were: cannabis (7.6%; increased from 7.2% the previous year), powder cocaine (2.9%) and ecstasy (1.6%). Women in the reproductive years (18–44) were at the highest risk of developing substance use disorder;¹ furthermore, 45% of pregnancies and one-third of births in England were unplanned and substance misuse was often identified as a risk factor for unplanned pregnancy.² Almost one-third of drug users receiving substance misuse treatment were female, and over 90% of these women were of childbearing age (16–54 years).³ Trends in the USA paint a similar picture, with studies demonstrating an increased use of cannabis among both pregnant and non-pregnant reproductive-aged women⁴ and specifically among women during the first trimester of pregnancy.⁵ Indeed, a study examining national trends in the USA reported an increase of admissions to substance use treatment facilities for marijuana (cannabis) use during pregnancy from 29% in 1992 to 43% in 2012.⁶ It is clear that the use of cannabis has increased in the general population and in women of childbearing age; however, monitoring cannabis use during pregnancy remains difficult.

The prevalence of cannabis use in pregnancy varies widely and is largely affected by factors such as

socioeconomic status, age and ethnicity.^{7,8} Sometimes, there is discrepancy between self-reported use and toxicology results. Self-reported rates of cannabis use are relatively low, whereas direct or objective measures of use often indicate higher rates.^{9,10} For example, one study found that out of 100 postpartum women, 11% disclosed cannabis use, whereas 14% tested positive by urinalysis and 28% by hair analysis.⁷ This discrepancy in reporting makes it difficult to fully ascertain the prevalence of cannabis use during the perinatal period and might indicate an underlying reluctance to disclose cannabis use which is likely to affect the quality of care and support provided to women who use cannabis during pregnancy.

Although current evidence indicates increasing prevalence of cannabis use, particularly in young women,¹ this is an evolving field with limited guidance. This study is an up-to-date narrative review of literature to guide doctors and other clinicians who often find themselves in ethically, clinically and legally challenging situations in the management of pregnant women who use cannabis.¹¹ We reviewed the ethics of cannabis use in pregnancy to give clinicians an evidence-based grounding in their principles of management, particularly when the dilemma of risks and benefits of cannabis use is heightened by advancements in medicinal

cannabis, against the backdrop of previously known risks. Based on our findings, we recommend targeted interventions at different perinatal stages to contribute to policy discussions in local healthcare services and facilitate developing regional and national guidelines.

Legalisation or decriminalisation

Legalisation refers to an approach that would remove all legal sanctions and penalties for possession and use of a drug. In this scenario, the government may establish regulations to manage licensing and to control the manufacture, quality, purity and supply of the drug, leading to it being more freely available to the general public (e.g. alcohol). In comparison, decriminalisation refers to an approach that would remove any criminal penalties despite it still being illegal to possess and use the drug (i.e. possession for personal use would not lead to a prosecution).^{12,13} Although decriminalisation of cannabis may seem to be an effective approach that recognises the potential harm and might be more favourably adopted by society, others claim that decriminalisation may only appear to be promising, as ‘a decriminalised drug is not legal, nor strictly illegal, depending on certain circumstances, nor is it necessarily of any better quality as it comes from the same sources as any other illegal drug’.¹³ Therefore the policy relies on authorities overlooking drug consumption and cannot adequately deal with the rising health concerns.

In light of the increasing evidence supporting the use of medicinal cannabis, there have been international calls for reform and review of drug policies on cannabis and cannabis-related products.¹⁴ Medicinal cannabis is currently legal in 33 states in the USA¹⁵ and countries such as Germany, Belgium, Spain, Italy, Australia and Canada.¹⁴ The oromucosal spray of cannabis (Sativex) for the treatment of multiple sclerosis was given regulatory approval in 30 countries.¹⁴ Changes in policy seem to meet public approval as there was a 5% increase to 48% in the public support for legalising cannabis, following the UK government legalising some medicinal cannabis products in 2018.¹⁶ Although the UK government legalised the use of medicinal cannabis,¹⁷ it retained the existing legislation for recreational use, listing cannabis as a Class B controlled drug under Part II, Schedule 2, of the Misuse of Drugs Act 1971 and Schedule 1 of the Misuse of Drugs Regulations 2001, stating that ‘it is unlawful to possess, supply, produce, import or export this drug except under a Home Office license’.¹⁸ Twenty-two percent of 1690 respondents in the YouGov survey said anyone should be allowed to cultivate their own drug.¹⁶

However, findings from international research have highlighted that decriminalising or legalising cannabis could lead to an increase in use, both among adults who have previously used cannabis and among those who may not have ordinarily used it (e.g. adolescents).^{19–22} For example, many states in the USA and some countries in Europe that have legalised cannabis show an increase in cannabis use and dependence, including among women of child-bearing age.²³ Although it is difficult to draw conclusions regarding the causal impact of decriminalisation on cannabis use (as trends are often different across age groups and

across time),²⁰ many factors, including perception of benefit and risk, increased drive towards autonomy, advances in pharmaceutical science and technology and financial motivation, have been identified as responsible for this wave of interest.^{23–25}

Thus, liberalising cannabis policies may lead to an increase in cannabis use in the preconception, prenatal and postpartum period,^{26,27} but there is a clear lack of guidance available for clinicians working with women who may use cannabis during the perinatal period. It is critical to establish guidance, especially as recreational cannabis use in pregnancy can sometimes be associated with psychiatric comorbidity, disrupted parental care, and poor maternal and fetal outcomes²⁸ (but see also^{29,30}). Some use cannabis to manage nausea in pregnancy, albeit against medical advice,³¹ while conversely chronic use of cannabis has been associated with hyperemesis syndrome.³² Furthermore, there is a potential for medicinal cannabis to be used to treat menstrual disorders and menopausal symptoms, including hot flushes, anxiety and mood changes, insomnia, pain, reduced libido and fatigue,³³ but there is limited research exploring the impact of medicinal cannabis use during pregnancy.³⁴ Limitations in information available can affect the clinician’s ability to make informed decisions to support care in this group. Clinicians may therefore find themselves in an ethically and clinically challenging position, balancing the health benefits of cannabis against the potential risks that may be incurred during pregnancy.

Method and findings

We conducted a narrative review, performing searches on relevant databases (PubMed, MEDLINE, Embase, CINAHL, PsycInfo and Google Scholar) using the search terms: ‘cannabis’, ‘marijuana’, ‘tetrahydrocannabinol’, ‘THC’, ‘cannabidiol’, ‘CBD’, ‘cannabinoid’, ‘pregnancy’, ‘medical’, ‘medicinal’, ‘risk’, ‘ethics’, ‘management’, ‘legalisation’. All searches were limited by publication date (2006–2021). We identified 218 articles that met the search criteria; these were then screened and assessed independently by the authors for quality of evidence (e.g. large sample size, UK and international studies with multiple sites, studies that addressed confounders raised in limitations of previous studies) before inclusion in the review (111 articles). We excluded 107 articles with similar but no additional relevant information.

Ethics approval

Ethical approval was not necessary for the research and writing of this review.

Cannabinoid science

There are over 100 cannabinoids and other components in the cannabis plant, with tetrahydrocannabinol (THC) and cannabidiol (CBD) being the most studied.³⁵ THC gives the recreational ‘high’ and CBD to some extent counteracts the psychoactive effect of THC.³⁵ The phytocannabinoids bind

to the endocannabinoid receptors CB₁ and CB₂, while also interacting with other neural transmission systems.^{36–38} CB₁ and CB₂ are G-protein-coupled receptors. CB₁ receptors have psychoactive properties and are expressed in the central nervous system, gastrointestinal system, adipocytes, liver tissue and skeletal muscle. CB₂ receptors, which are more restricted, are expressed in immune cells located in the tonsils, thymus, spleen and bone marrow, as well as in the enteric nervous system within the gastrointestinal tract.³⁹ CB₁ binding exerts its physiological and pathological effects by regulating presynaptic Ca⁺⁺ levels, thus leading to a reduced release of neurotransmitters.⁴⁰ At an early stage of human embryonic and fetal development (14 weeks), the endocannabinoid system develops in relation to other neurotransmission systems, and prenatal cannabis exposure could therefore lead to changes in activities of brain areas such as the prefrontal cortex, the mesolimbic system, the striatum and the hypothalamic–pituitary axis, with potential for long-lasting or delayed effects on executive function or regulation of the emotional system and cognition.^{15,25,40}

Medical use of cannabis

The earliest recorded date for cannabis use as a medicine is 4000 BCE in China, and in the 19th and 20th centuries it has been used to treat migraine, neuropathic and musculoskeletal pain, and in childbirth.⁴¹ Following the discovery of the CB₁ and CB₂ cannabinoid receptors, research showing increasing medicinal properties has heightened interest in the legalisation of cannabis, specifically for medical use and to facilitate further research.⁴¹ Some formulations are currently used in treating resistant spasticity in multiple sclerosis, and nausea and vomiting induced by chemotherapy.⁴² CBD oral solution (Epidyolex[®]) has been classified as a Schedule 2 controlled drug in the UK for the treatment of seizures associated with Lennox–Gastaut and Dravet syndromes.⁴² Furthermore, in a recent randomised placebo-controlled phase 2 trial to establish the safety of dosing of CBD in non-pregnant individuals with cannabis use disorder, 400 and 800 mg appeared safe.⁴³ In the UK, medicinal cannabis can be prescribed only by doctors on the General Medical Council's (GMC's) specialist register with special interest in the condition being treated, and under strict prescribing guidelines stipulated by the National Institute for Health and Care Excellence (NICE), GMC and NHS England.⁴⁴

Guidance on use of cannabis

Recent guidance from the UK's Food Standards Agency (FSA) on the increasingly popular oral non-medicinal CBD-containing products such as beverages (beer, spirits, wine, coffee and soda style drinks), oils (tinctures, drops, syrup, olive oils) and confectionary (gum drops, chocolate) limited their use to no more than 70 mg daily. It recommended that non-medicinal CBD products should not be used by pregnant or breastfeeding individuals, extrapolating from data on animal research which showed fetal harm.⁴⁵ Likewise, in the USA, the US Food & Drug Administration (FDA) also highlighted the potential harm from cannabis (also referred to as marijuana) and although it approved

the controlled use of medical cannabis (Epidyolex[®]), given the risks, which include serious liver injury, it strongly advises against the use of CBD, THC and marijuana in any form during pregnancy or while breastfeeding.^{46,47}

Although guidance from official sources is relatively clear, there is a risk that information from other sources may provide conflicting advice to consumers. For example, the FDA reported that it has issued warning notices against three companies making unsubstantiated claims about their cannabis-based products' 'ability to limit, treat or cure cancer, neurodegenerative conditions, autoimmune diseases, opioid use disorder, and other serious diseases, without sufficient evidence and the legally required FDA approval'.⁴⁶ Moreover, a study conducted in Colorado demonstrated that cannabis dispensaries often gave conflicting and sometimes incorrect information regarding the use of cannabis-based products during pregnancy. A mystery caller from the study team contacted 400 dispensaries stating that she was 8 weeks pregnant and was looking for advice regarding cannabis-based products for morning sickness. It was found that 35.7% of dispensaries endorsed the use of cannabis-based products during early pregnancy, 65% based their recommendation on personal opinion and only 31% recommended speaking to a healthcare provider without prompting.⁴⁸ This demonstrates the importance of presenting a united front with official regulations and standards of advice, and of raising public health awareness regarding medical use of cannabis during pregnancy that is informed by scientific evidence.

Cannabis and mental illness

Many people with psychological or mental disorders self-medicate with cannabis;³⁷ however, the evidence on treatment efficacy is limited and often mixed.⁴⁹ For example, a review of research into the use of CBD in treating fibromyalgia reported that, although findings seemingly suggested that CBD is a safe and effective treatment, the studies all suffered from methodological limitations that prevent firm conclusions being drawn.⁵⁰ A recent systematic review and meta-analysis concluded that there is insufficient evidence that cannabinoids are effective in treating mental disorders, including depressive disorders and symptoms, anxiety disorders, attention-deficit hyperactivity disorder (ADHD), Tourette syndrome, post-traumatic stress disorder (PTSD) and psychosis.⁵¹ Another systematic review demonstrated tentative support for the efficacy of cannabis in social anxiety and as an adjunct in schizophrenia; however, the evidence in treating sleep disorders and PTSD was relatively weaker and there was no benefit of using cannabis to treat depression or mania.⁵² The authors concluded that the recommendation of cannabinoid-based interventions for psychiatric disorders would be premature at the moment and further warned against using products with high delta-9 THC content, particularly by young people.⁵² This is important to note as other studies have suggested that recreational cannabis with high THC content (e.g. skunk) is associated with mental health problems and physiological manifestations, including psychosis, dizziness, euphoria, drowsiness, dry mouth, confusion, somnolence and fatigue.^{23,41,53} It is clear that more research is required

with human participants (rather than animals) to examine the safety of different strains and components, dosage and routes of administration.⁴¹

Advocates of medicinal cannabis suggest that it could reduce the rates of opioid dependence and deaths from overdose if patients switch from opioid-based pain relief to cannabis, as the risk of dependence is much lower and there are no reports of death from cannabis overdose.⁴¹ However, an international survey of 55 240 cannabis users published in 2020 found that the most commonly used classes of cannabis – sinsemilla and herbal (30.3%) and sinsemilla, herbal and hashish (20.4%) – were associated with increased dependence severity, while the class of concentrates and sinsemilla (1.7%) was associated with a record of diagnosed mental disorder.⁵⁴ The conflicting evidence also highlights the need for further research.

Impact of cannabis use in pregnancy

Factors associated with the continued use of cannabis during pregnancy include history of cannabis use disorder (2.77 times more likely to continue), frequent cannabis use (daily or weekly compared with monthly), not completing high school, having a psychiatric disorder, biological father's cannabis use and being unmarried.^{6,55} Personal (e.g. marital status, ethnicity) and area characteristics (e.g. urban, cosmopolitan or rural environments) as well as lifestyle factors can contribute to drug use; however, researchers warn that these factors often interact so it would be difficult to isolate the influence of any one of these characteristics on cannabis use.¹

Studies have reported short-term risks for individuals who use CBD in pregnancy. This includes impaired short-term memory and motor coordination, altered judgement, paranoia, dependence disorder, psychosis, injuries, motor vehicle collisions and suicide.^{53,56} Indeed, maternal suicide remains the leading cause of direct deaths occurring within a year after the end of pregnancy;⁵⁷ 8% of the women who died during or up to a year after pregnancy in the UK between 2016 and 2018 were at severe and multiple disadvantages, also known as the 'toxic trio' of mental health diagnosis, substance misuse and domestic abuse.⁵⁷

Cannabis use in pregnancy has also been associated with still-birth, preterm labour, low birth weight, 'small for gestational age' and two-fold increased risk of admission to a neonatal intensive care unit.^{58–60} Gestational cannabis use may also be linked to maternal fatty liver, obesity, insulin resistance and increased risk of gestational diabetes mellitus (GDM).⁶¹ In a more recent study, prenatal cannabis use was associated with a 50% increased likelihood of low birth weight, independent of confounders, although no association was found for small for gestational age, preterm birth and neonatal intensive care unit admission.⁶² Furthermore, another recent population-based retrospective cohort study that included 661 617 pregnancies reported that cannabis users ($n = 9427$) were twice as likely to have a preterm birth compared with non-users, after adjusting for confounding variables, including tobacco use.⁶³

Cannabis use can also affect breastfeeding as evidence suggests that THC and CBD can accumulate in breast milk.⁶⁴ However, this remains a vastly understudied area.

As THC is highly fat soluble it can be excreted into breast milk^{65,66} and released slowly over days to weeks, depending on extent of use. This is a concern as evidence suggests that breastfeeding mothers sometimes increase their consumption of cannabis after childbirth.⁶⁴ Furthermore, cannabis use while breastfeeding appears to be associated with a decrease in infant motor development at 1 year of age.⁶⁷ However, it is difficult to draw clear conclusions owing to small sample sizes and difficulty in separating the effect of exposure to cannabis *in utero* which continues into the postnatal period through lactation from exposure that occurs only during lactation. As studies (the majority of which are animal rather than human⁶⁸) indicate conflicting outcomes, women who are unable to abstain are advised not to breastfeed within 1 h of inhaling or consuming cannabis, with the aim of reducing the infant's exposure to the highest concentration of cannabis in breast milk.⁶⁹

The long-term effect of cannabis use should also be borne in mind as intrauterine exposure to cannabis has been found to increase the likelihood of initiation of cannabis and other substance use in adolescents.⁷⁰ Prenatal exposure may also be linked to developing psychosis-like and affective disorders^{71,72} and ADHD.²⁴ It is also linked with reduced attention and executive functioning skills, poorer academic achievement and behavioural problems.⁷³ This might be because maternal prenatal cannabis use adversely affects growth of fetal and adolescent brains,^{29,55} as demonstrated in the reduction of inhibitory interneurons in the hippocampal formation of adult rats.⁷⁴ In more serious cases, children raised in families where there is substance misuse can suffer negative effects on long-term health and well-being.⁷⁵ Parents may be unable to supervise their children and meet their needs appropriately, which could lead to emotional abuse and neglect.⁷⁶ There are further concerns about physical abuse of children if parents have difficulty controlling their own emotions. These children can suffer from behavioural, emotional and cognitive problems and experience long-term psychological effects from their experience of being raised in a chaotic household.⁷⁵

Although research suggests that there is a high rate of abstinence from cannabis during pregnancy (with a discontinuation rate of around 77–78%),^{77,78} a high number of individuals also relapse, with 41% using cannabis within 3 months after delivery.⁷⁷ Several characteristics could influence the rate of abstinence and relapse of cannabis use during the perinatal period. One study found that women with a post-secondary education and lower scores of depression and anxiety were more likely to attain abstinence, whereas those aged 21 years and below and with a diagnosis of depression were more likely to relapse in the postpartum period.⁷⁷ Furthermore, given the high degree of concurrent substance misuse, women may substitute smoking cigarettes for alcohol, marijuana or cocaine use as they perceive cigarettes to be more socially acceptable and less harmful compared with illicit substances and alcohol.⁷⁷ Thus, taking personal characteristics and the perception of harm into consideration is important for targeted perinatal interventions aimed at managing risks associated with cannabis use.

Ethical considerations of drug use in pregnancy

The use of medicinal cannabis for different conditions has gained in popularity despite evident risks.⁷⁹ Consequently, clinicians are often torn in the moral conflict and the debate around legalisation of medicinal and recreational cannabis use.^{11,23} Although legalisation and decriminalisation of cannabis across the world indicate a changing perception on the ethics of cannabis use, the stigma from the legacy of prohibition and ongoing restrictions are believed to stall research.^{80,81} However, the principles of beneficence and non-maleficence, respect for autonomy and justice, weighing costs and benefits, and patient-centred decision-making can all support evidence-based practice and can guide clinicians to recommend or prescribe cannabis when indicated.^{80,82}

Claims that a fetus has full rights and that the right to life⁸³ or prenatal care⁸⁴ override the mother's right to autonomy or inviolability⁸⁵ have led to jailing of women in the USA who took drugs in pregnancy or after birth if found positive on drug screening.⁸⁶ It has been argued that criminalising substance misuse in pregnancy would cause more harm than good as the worry of penalisation may lead mothers away from adequate perinatal care and support for cannabis use disorder.⁸⁶ By pitting the rights of the mother and fetus against each other, the discussion can easily become moralistic rather than evidence based and can perpetuate stigma associated with substance misuse during pregnancy. Furthermore, punitive measures place healthcare workers in difficult positions as they have also questioned the policy of drug screening in pregnancy without consent, their role in policing women who take cannabis in pregnancy and the disproportionate impact on women from minority ethnic groups.^{86,87}

The principle of non-maleficence supports advising against cannabis use in pregnancy. However, for those who choose to use cannabis in pregnancy despite the warning, Bewley argues that as the fetus is a future member of society, society has a 'legitimate interest' in its welfare and should aim to support women who take drugs and minimise preventable harms to babies by offering incentives rather than using threats, coercion or punishment.⁸⁵ Harris also argued in favour of a gender- and equality-based approach to resolving the dilemma rather than perpetuating the age-long conflict-based ethics.¹¹ In this model, clinicians faced with ethical dilemmas should attempt to understand pregnant women and their decisions within their broad social networks and communities, ask how the clinician's personal standpoint influences outcomes judged to be ethical and determine whether the clinician's ethical formulations reduce or enhance existing gender, class or racial inequality.¹¹ This seems to be a more appropriate solution as there is no evidence to suggest that penalising drug use in the perinatal period leads to better maternal or fetal outcomes.⁸⁶ Bridging the gap between different views requires clarification of what constitutes benefits, harm and rights in relation to cannabis use as these are the core issues contended in the mother–fetus drug use debate.⁸³

Proponents of recreational drug use contend that the government should intervene only when there is a high risk of causing harm to others.⁸⁸ Prohibitory laws based on harm reduction have been challenged as punitive⁸⁹ and it has been proposed instead that harm reduction should be

based on four principles: (a) drug use should be viewed neutrally, not moralistically; (b) a drug user is a citizen and member of a community, not a deviant individual or only an object of measures; (c) drug policy should be based on practice and science, not on ideologies and dogmatism; and (d) drug policy should respect human rights and support justice, not trample on them in the name of a 'war on drugs' or the goal of a drug-free society.⁹⁰ These principles may also be useful in the context of healthcare, in that clinicians should ensure that women who use cannabis during pregnancy are treated in a neutral, non-stigmatising way and are supported to make healthcare decisions based on evidence, rather than ideology.

Table 1 shows ethical considerations and recommended approaches to navigating ethical dilemmas of cannabis use in pregnancy.

Implications for doctors and other clinicians

It is important for doctors and other healthcare practitioners involved in supporting women of childbearing age to be aware of the benefits of medicinal cannabis and potential risks of cannabis use in pregnancy.⁹¹ This helps in discussing potential risks with patients and supporting them to make informed decisions.^{24,80} With the legalisation of medicinal cannabis⁴¹ and ongoing research into other areas of potential benefit, it is perhaps more challenging to correct the common perception that cannabis is relatively harmless.²⁵ For example, in a survey of 51 healthcare providers to pregnant women in the USA, the providers (2nd–4th year obstetrics residents, nurse midwives and practitioners and faculty physicians) reported that they perceive cannabis use in pregnancy as less dangerous than use of other illicit drugs, while expressing the view that many pregnant women do not perceive cannabis as a drug.⁹² The perception of low risk associated with cannabis use has also been reported among young people,²⁴ and more research is required to ascertain the effects of parental cannabis use on parenting and child and adolescent development.^{71,93} Table 2 provides a summary of interventions at different perinatal stages. Some of these interventions are targeted at vulnerable women or at-risk groups, whereas others are indicated for public health.

Table 1 Ethical principles and recommended approaches in navigating ethical dilemmas concerning cannabis use in pregnancy

Ethical principle	Considered approach
Beneficence	Discuss benefits and recommend cannabis-based medicinal products when indicated based on evidence
Non-maleficence	Discuss short-term and long-term risks to the mother, fetus and infant or child
Respect for autonomy	Assess whether the patient has capacity; obtain informed consent for procedures; demonstrate weighing of costs and benefits in collaboration with the patient- and patient-centred decision-making
Justice	Ensure adequate access to treatment and care irrespective of decision to take cannabis-based medicinal products

Table 2 Indicated or targeted interventions by healthcare professional at different perinatal stages

Perinatal stage	Indicated or targeted intervention
Prenatal	<p>Provide psychoeducation, assess motivation to change and discuss risk–benefit analysis to enable patient to make an informed decision about cannabis use.</p> <p>Use opportunities to embed contraception and precontraception care discussions during health and non-health contacts for women of childbearing age.</p> <p>Help women to maximise health and well-being before pregnancy by improving lifestyle and diet.</p> <p>Targeted intervention and support (referral to liaison or community psychiatry and/or substance misuse clinic) for high-risk vulnerable women with history of cannabis use disorder, frequent cannabis use, concurrent tobacco or other substance use, and history of psychiatric disorder.</p> <p>Identify and attempt to address social problems that may lead to low levels of happiness, which have been associated with drug use. Particular attention should be paid to identifying determinants of social inequalities so as to consider referral for social support.</p> <p>Public health interventions and multimedia campaigns to educate women of childbearing age-group regarding risks associated with cannabis use.</p>
Antenatal	<p>The following factors should be noted in booking clinic and follow-up as they are associated with continued use of cannabis during pregnancy: history of cannabis use disorder, frequent cannabis use (daily or weekly compared with monthly), level of education, having a psychiatric disorder, biological father's cannabis use, and marital status.</p> <p>History of oral consumption of non-medicinal CBD-containing foods or products should also be noted.</p> <p>Multiple urine screens should be offered throughout pregnancy owing to underreporting in clinical interviews; reassurance may need to be given that this is not punitive but meant to identify those requiring support.</p> <p>Look out for cannabis withdrawal syndrome (CWS) in regular and dependent users – symptoms from three of the following groups within 7 days of stopping cannabis: irritability, anger or aggression; nervousness or anxiety; sleep disturbance; appetite or weight disturbance; restlessness; depressed mood; somatic symptoms such as headaches, sweating, nausea, vomiting or abdominal pain</p> <p>Provision of integrated clinics for pregnant women which offer a 'one-stop shop' for antenatal care, primary care, counselling services for substance misuse, parenting and social care support.</p> <p>Use of evidence-based treatment such as motivational enhancement therapy and cognitive-behavioural therapy with abstinence-based incentives for the treatment of cannabis use disorders.</p>
Postnatal	<p>A multidisciplinary approach involving the general practitioner, midwife, obstetrician, paediatrician and social worker is important, so clear communication between all healthcare professionals involved in the care of the patient is necessary. Referral to liaison or community psychiatry and/or substance misuse professionals may be required.</p> <p>Monitoring of withdrawal symptoms in newborn by paediatrician.</p> <p>Cannabis use is not recommended while breastfeeding, based on current evidence, but if a nursing mother wants to use cannabis, support should be provided in line with the ethical principles discussed above regarding the use of cannabis-based products for medicinal or recreational use.</p>

Comprehensive assessment within a multidisciplinary framework

We emphasise the importance of a multidisciplinary approach within health and social services because of the impact of substance misuse on the fetus, the mother and the newborn child.⁹⁴ We also advocate supporting women at risk to maximise their health and well-being before pregnancy by improving lifestyle and diet. Accurate identification of cases, use of motivational interviewing techniques and access to cognitive-behavioural therapy (CBT) are vital.²⁸ Comprehensive assessment, the cornerstone of management, should consider the risk to the physical and mental health of the mother during pregnancy, and ongoing child-care and parenting issues. This should lead to a plan and care package involving well-coordinated, multidisciplinary care with a specialist drug service working collaboratively with the general practitioner (GP), midwife, obstetrician, paediatrician and social worker.⁹⁴

GPs' ongoing relationship with patients enables them to establish rapport in order to discuss preconception health and promote positive changes in health and lifestyle. The World Health Organization (WHO) recommends the use of interventions that are brief, structured and require

easy-to-administer tools. These interventions include information and motivational components that have been effective in primary care settings.^{81,95} Furthermore, a Cochrane review found that a combination of motivational enhancement therapy (MET) and CBT with abstinence-based incentives had stronger evidence in the treatment of cannabis use disorder compared with drug counselling, social support, relapse prevention and mindfulness meditation.⁹⁶

Identifying cannabis withdrawal syndrome (CWS)⁹⁷ in regular and dependent users is important as it can confound mental illness or early signs and symptoms of pregnancy such as nausea, headache and fatigue, which is why some patients present late for treatment of mental illness or for antenatal care.⁹⁴ The DSM-5 diagnosis of CWS requires at least three of the following seven groups of symptoms developing within 7 days of reduced cannabis use: irritability, anger or aggression; nervousness or anxiety; sleep disturbance; appetite or weight disturbance; restlessness; depressed mood; and somatic symptoms such as headaches, sweating, nausea, vomiting or abdominal pain.⁹⁸ This underscores the importance of training for healthcare workers in identifying symptoms and signs of cannabis misuse, particularly in techniques to improve the accuracy of obtaining a history of cannabis misuse in pregnancy.⁹⁹

Women may hesitate to disclose cannabis use owing to fear of judgement and concerns that their parenting ability may be questioned. Day & George⁹⁴ described the difficulty of accurately reporting the prevalence of high-risk drug use in pregnancy owing to underreporting resulting from ‘feelings of shame, denial and stigma experienced by the drug user, lack of awareness among professionals in antenatal services, the presence of comorbid psychiatric disorders, and sociocultural barriers that may prevent a thorough assessment’. Asking about type, quantity and impact of substance use by a trained professional is vital in evaluating risk. Wilson and colleagues have suggested questions to consider pertaining to substance misuse in the preconception or perinatal period. These should focus on empathic enquiry to assess the type and number of substances used, care and support available, impact on daily life and potential motivators for change.¹⁰⁰ Roncero and colleagues advocate harm minimisation strategies by early detection and alerting pregnant women to the risks of cannabis use to themselves and the unborn baby.²⁴ Owing to the likely underestimation from self-report (which may be linked to guilt, fear of legal consequences, stigma and social service referral), multiple urine screens during pregnancy may be a more reliable method to assess and monitor exposure to substances.²⁴ Urine toxicology in a group of pregnant females identified twice as many cannabis users compared with self-report (4.9 v. 2.5%).¹⁰¹ Maternal hair and the meconium of the newborn have also shown higher detection rates of cannabis use compared with clinical interviews.¹⁰² The collection window for urine toxicology is 24–48 h (longer in regular consumers of cannabis), whereas maternal hair provides the advantage of giving information on the presence of THC over several months, given that 1 month corresponds to roughly 1 cm of hair growth from the scalp; however, testing is limited by hair type, hair products, amount collected and processing. Meconium cannabinoid testing is more expensive and is limited by the narrow collection window of 72 h.¹⁰³

It is also important to ask patients about their consumption of non-medicinal CBD-containing foods or products, because of potential adverse effects. As stated earlier, there is limited research on the effects of CBD on embryonic development; however, several animal studies suggest that CBD can cause fetal harm.¹⁰⁴ More specifically, animal studies on rhesus monkeys, dogs and rats showed that CBD exposure resulted in problems such as hepatotoxicity, immunotoxicity, reproductive toxicity, changes to organ weights (i.e. increase in weight of liver, kidneys, heart, thyroid, thymus, spleen and adrenal glands and decrease in testicular weight) and alterations to cytochrome P450 drug-metabolising enzymes.¹⁰⁴ Obtaining relevant information during prenatal or antenatal reviews therefore helps to target interventions using a person-centred approach.²⁴ Finally, the high rate of relapse of cannabis use 3 months after delivery indicates that ongoing support should be made available to susceptible women and their infants in the postnatal period.⁷⁷

Cannabis use during breastfeeding is a key dilemma for clinicians as the benefits of breastfeeding are very well known but early evidence indicates that CBD and THC can be transferred to the infant via breast milk.⁶⁵ Current guidelines recommend abstaining from cannabis use during breastfeeding,¹⁰⁵ but clinicians may still be conflicted between

encouraging breastfeeding for the benefit of the child versus encouraging abstinence from cannabis-based products despite the potential medicinal benefits for the mother.¹⁰⁶ Although research into cannabis use during breastfeeding is in its infancy, it is clear that a system-wide, multidisciplinary approach is needed to inform nursing mothers about the effects of cannabis on infants.¹⁰⁷ For example, pharmacists and lactation consultants are in unique positions and may be able to identify those who are using cannabis, offer advice on abstinence, support with education on the known risks and benefits of cannabis use during breastfeeding and provide referrals for treatment, if required.^{108,109}

Recommendations and conclusions

Although there may be an increasing trend in the use of medicinal cannabis¹¹⁰ both among those prescribed it for medical conditions and those self-medicating because of perceived efficacy in managing their emotional and mental symptoms, more research is needed (in human rather than animal studies) to determine the safety of different strains and components, dosage and routes of administration, effect sizes for clinical outcomes and comparisons with existing treatments. Legalisation or decriminalisation may lead to the increased use of cannabis in pregnancy despite persisting risks. Clinicians should adopt a harm minimisation strategy when navigating the dilemma of the rights of the fetus versus those of the mother.

Pregnancy offers a ‘window of opportunity’ to identify and treat substance misuse in this vulnerable group along with other psychosocial problems associated with substance misuse in pregnancy.²⁷ From our research, we have presented a stepwise approach to providing care and intervention targeting the prenatal, antenatal and postnatal stages detailed in Table 1.

Doctors treating pregnant women need to keep their knowledge up to date and be aware of the impact of cannabis use in the perinatal period, especially as studies show that cannabis use is underreported. This will enable the provision of targeted intervention and support, including adequate information for pregnant women to make an informed decision about cannabis use.

Limitations

The findings of this review should be seen in light of some limitations. This paper is a narrative review aiming to offer an objective analysis in the current context of decriminalisation and licensing of cannabis for medical use and its ethical considerations during pregnancy. A systematic review with rigorous methodological approaches, considering new and emerging evidence assessing the impact of licensing of medicinal cannabis in the UK, may be able to draw more robust conclusions on this topic of significant public health interest.

About the authors

Abdulazeem Towobola, MBChB, MRCPsych, MA, is a consultant psychiatrist with Kent and Medway NHS and Social Care Partnership Trust, UK. **Basirat Towobola**, MBChB, MRCOG, is a consultant obstetrician and gynaecologist with East Sussex Healthcare NHS Trust, UK. **Bosky Nair**, MBBS, MRCPsych, MSc, PG Dip HCL, is a consultant perinatal psychiatrist with Kent and

Medway NHS and Social Care Partnership Trust, UK. **Arti Makwana**, MSc, is a research facilitator with Kent and Medway NHS and Social Care Partnership Trust, UK.

Data availability

The authors confirm that the data supporting the findings of this study are available within the article, and supplementary materials (methods, literature search) are available from the corresponding author, A.T., upon reasonable request.

Acknowledgement

We thank Ann Foreman (Learning and Library Lead, Maidstone and Tunbridge Wells NHS Trust) for her support with the literature search.

Author contributions

Each author has substantially contributed to researching and drafting this manuscript. A.T. is the lead author who conceptualised and drafted the framework of the manuscript. He was involved in researching, collating ideas and writing up. B.T. and B.N. were involved in researching, analysing and writing up. A.M. contributed to the draft manuscript and the revised manuscript, particularly the methodology.

Funding

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Declaration of interest

B.N. and A.M. receive grants from the Interreg 2 Seas Perinatal mental Health (PATH) Project, outside the submitted work.

References

- Home Office. Drug Misuse: Findings from the 2018/19 Crime Survey for England and Wales (*Statistical Bulletin 21/19*). Home Office, 2019.
- Mann S. Health matters: reproductive health and pregnancy planning. *Health Matters* 2018; 26 June (<https://publichealthmatters.blog.gov.uk/2018/06/26/health-matters-reproductive-health-and-pregnancy-planning/> [cited 27 Jun 2020]).
- Office for National Statistics. *Drug Misuse in England and Wales: Year Ending March*. ONS, 2020 (<https://www.ons.gov.uk/peoplepopulationandcommunity/crimeandjustice/articles/drugmisuseinenglandandwales/yearendingmarch2020>).
- Brown Q, Sarvet A, Shmulewitz D, Martins S, Wall M, Hasin D. Trends in marijuana use among pregnant and nonpregnant reproductive-aged women, 2002–2014. *JAMA* 2017; **317**: 207–9.
- Volkow ND, Han B, Compton WM, McCance-Katz EF. Self-reported medical and nonmedical cannabis use among pregnant women in the United States. *JAMA* 2019; **322**: 167–9.
- Martin C, Longinaker N, Mark K, Chisolm M, Terplan M. Recent trends in treatment admissions for marijuana use during pregnancy. *J Addict Med* 2015; **9**: 99–104.
- Beatty JR, Sviki DS, Ondersma J. Prevalence and perceived financial costs of Marijuana versus Tobacco use among Urban low-income pregnant women. *Addict Res Ther* 2012; **3**(4): 1000135.
- Ko JY, Farr SL, Tong VT, Creanga AA, Callaghan WM. Prevalence and patterns of marijuana use among pregnant and nonpregnant women of reproductive age. *Am J Obstet Gynecol* 2015; **213**: 201.e1–e10.
- El Marroun H, Tiemeier H, Jaddoe VWV, Hofman A, Verhulst FC, van den Brink W, et al. Agreement between maternal cannabis use during pregnancy according to self-report and urinalysis in a population-based cohort: the generation R study. *Eur Addict Res* 2011; **17**: 37–43.
- Yonkers KA, Howell HB, Gotman N, Rounsaville BJ. Self-report of illicit substance use versus urine toxicology results from at-risk pregnant women. *J Subst Use* 2011; **16**: 372–80.
- Harris L. Rethinking maternal-fetal conflict: gender and equality in perinatal ethics. *Obstet Gynecol* 2000; **96**(5, part 1): 786–91.
- Bean P. *Legalising Drugs: Debates and Dilemmas*. Policy Press, 2010.
- Dalgarno P, O'Rawe S, Hammersley R. Illegal drugs in the UK: is it time for considered legalisation to improve public health? *Drug Sci Policy Law* 2021; **7**: 1–9.
- Hurley R. Cannabis, cannabis everywhere: UK to review medical cannabis policy as Canada plans imminent legalisation for all uses. *BMJ* 2018; **361**: k2695.
- National Conference of State Legislatures. *State Medical Marijuana Laws*. NCSL, 2020 (<https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx> [cited 27 Jun 2020]).
- Banes C. *Support for legalising cannabis growing among British public, survey finds*. Independent, 14 July 2019 (<https://www.independent.co.uk/news/uk/home-news/cannabis-legalisation-uk-public-support-yougov-survey-marijuana-rob-wilson-a9004101.html#> [cited 22 October 2021]).
- Home Office. Government announces that medicinal cannabis is legal. GOV.UK, 2018; 11 Oct (<https://www.gov.uk/government/news/government-announces-that-medicinal-cannabis-is-legal> [cited 21 Jun 2021]).
- Home Office. *Drug Licensing Factsheet – Cannabis, CBD and other Cannabinoids*. Home Office, 2019 (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/825872/factsheet-cannabis-cbd-and-cannabinoids-2019.pdf).
- Shi Y, Lenzi M, An R. Cannabis liberalization and adolescent cannabis use: a cross-national study in 38 countries. *PLoS One* 2015; **10**(11): e0143562.
- Williams J, Bretteville-Jensen AL. Does liberalizing cannabis laws increase cannabis use? *J Health Econ* 2014; **36**: 20–32.
- Cerdá M, Wall M, Feng T, Keyes KM, Sarvet A, Schulenberg J, et al. Association of state recreational marijuana laws with adolescent marijuana use. *JAMA Pediatr* 2017; **171**: 142–9.
- Cerdá M, Mauro C, Hamilton A, Levy NS, Santaella-Tenorio J, Hasin D, et al. Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. *JAMA Psychiatry* 2020; **77**: 165–71.
- Murray R, Hall W. Will legalization and commercialization of cannabis use increase the incidence and prevalence of psychosis? *JAMA Psychiatry* 2020; **77**: 777–8.
- Roncero C, Valriberas-Herrero I, Mezzatesta-Gava M, Villegas J, Aguilar L, Grau-López L. Cannabis use during pregnancy and its relationship with fetal developmental outcomes and psychiatric disorders: a systematic review. *Reprod Health* 2020; **17**(1): 25.
- Bahji A, Stephenson C, Tyo R, Hawken E, Seitz D. Prevalence of cannabis withdrawal symptoms among people with regular or dependent use of cannabinoids: a systematic review and meta-analysis. *JAMA Netw Open* 2020; **3**(4): e202370.
- Skelton KR, Hecht AA, Benjamin-Neelon SE. Recreational cannabis legalization in the US and maternal use during the preconception, prenatal, and postpartum periods. *Int J Environ Res Public Health* 2020; **17**(3): 909.
- Gnofam M, Allshouse AA, Stickrath EH, Metz TD. Impact of marijuana legalization on prevalence of maternal marijuana use and perinatal outcomes. *Am J Perinatol* 2020; **37**: 59–65.
- Forray A. Substance use during pregnancy. *F1000Res* 2016; **5**: F1000 Faculty Rev-887.
- Jaques S, Kingsbury A, Henshcke P, Chomchai C, Clews S, Falconer J, et al. Cannabis, the pregnant woman and her child: weeding out the myths. *J Perinatol* 2014; **34**(6): 417–24.
- Metz T, Borgelt L. Marijuana use in pregnancy and while breastfeeding. *Obstet Gynecol* 2018; **132**: 1198–210.

- 31 Westfall RE, Janssen PA, Lucas P, Capler R. Survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of its efficacy against 'morning sickness'. *Complement Ther Clin Pract* 2006; **12**: 27–33.
- 32 Braillon A, Bewley S. Cannabinoid hyperemesis syndrome: implications for pregnancy. *BMJ* 2019; **366**: l5587.
- 33 Ayonrinde O. Women, ethics, and cannabinoids. *Menopause* 2019; **26** (12): 1449.
- 34 Sarrafpour S, Urits I, Powell J, Nguyen D, Callan J, Orhurhu V, et al. Considerations and implications of cannabidiol use during pregnancy. *Curr Pain headache Rep* 2020; **24**(7): 38.
- 35 Mouhamed Y, Vishnyakov A, Qorri B, Sambi M, Frank SS, Nowierski C, et al. Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. *Drug Healthc Patient Saf* 2018; **10**: 45–66.
- 36 Pertwee R. Endocannabinoids and their pharmacological actions. *Handb Exp Pharmacol* 2015; **231**: 1–37.
- 37 Osborn L, Lauritsen K, Cross N, Davis A, Rosenberg H, Bonadio F, et al. Self-medication of somatic and psychiatric conditions using botanical marijuana. *J Psychoactive Drugs* 2015; **47**: 345–50.
- 38 Aizpurua-Olaizola O, Elezgarai I, Rico-Barrio I, Zarandona I, Etxebarria N, Usobiaga A. Targeting the endocannabinoid system: future therapeutic strategies. *Drug Discov Today* 2017; **22**: 105–10.
- 39 Wang X, Dow-Edwards D, Keller E, Hurd Y. Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. *Neuroscience* 2003; **118**: 681–94.
- 40 Sharapova SR, Phillips E, Sirocco K, Kaminski JW, Leeb RT, Rolle I. Effects of prenatal marijuana exposure on neuropsychological outcomes in children aged 1–11 years: a systematic review. *Paediatr Perinat Epidemiol* 2018; **32**: 512–32.
- 41 Barnes M. The case for medical cannabis. *BMJ* 2018; **362**: k3230.
- 42 NHS England. *Cannabis-Based Products for Medicinal Use: Frequently Asked Questions*. NHS England, 2020 (<https://www.england.nhs.uk/medicines-2/support-for-prescribers/cannabis-based-products-for-medicinal-use/cannabis-based-products-for-medicinal-use-frequently-asked-questions/#what-is-epidyoex> [cited 9 May 2021]).
- 43 Freeman TP, Hindocha C, Baio G, Shaban ND, Thomas EM, Astbury D, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. *Lancet Psychiatry* 2020; **7**: 865–74.
- 44 Freeman TP, Hindocha C, Green SF, Bloomfield MA. Medicinal use of cannabis based products and cannabinoids. *BMJ* 2019; **365**: l1141.
- 45 Food Standards Agency. *Cannabidiol CBD: Consumer Advice on Cannabidiol (CBD) Extracts*. FSA, 2020 (<https://www.food.gov.uk/safety-hygiene/cannabidiol-cbd> [cited 28 Jun 2020]).
- 46 US Food & Drug Administration. *Statement from FDA Commissioner Scott Gottlieb, M.D., on New Steps to Advance Agency's Continued Evaluation of Potential Regulatory Pathways for Cannabis-Containing and Cannabis-Derived Products*. FDA, 2019 (<https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-new-steps-advance-agencys-continued-evaluation> [cited 28 Jun 2020]).
- 47 US Food & Drug Administration. *What You Should Know about Using Cannabis, Including CBD, When Pregnant or Breastfeeding*. FDA, 2019 (<https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding> [cited 28 Jun 2020]).
- 48 Dickson B, Mansfield C, Guiai M, Allshouse AA, Borgelt LM, Sheeder J, et al. Recommendations from cannabis dispensaries about first-trimester cannabis use. *Obstet Gynecol* 2018; **131**: 1031–8.
- 49 Whiting P, Wolff R, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. *JAMA* 2015; **313**: 2456–73.
- 50 Cameron EC, Hemingway SL. Cannabinoids for fibromyalgia pain: a critical review of recent studies (2015–2019). *J Cannabis Res* 2020; **2**(1): 19.
- 51 Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. *Lancet Psychiatry* 2019; **6**: 995–1010.
- 52 Sarris J, Sinclair J, Karamacoska D, Davidson M, Firth J. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. *BMC psychiatry* 2020; **20**(1): 24.
- 53 Colizzi M, Murray R. Cannabis and psychosis: what do we know and what should we do? *Br J Psychiatry* 2018; **212**: 195–6.
- 54 Craft S, Winstock A, Ferris J, Mackie C, Lynskey MT, Freeman TP. Characterising heterogeneity in the use of different cannabis products: latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence. *Psychol Med* 2020; **50**: 2364–73.
- 55 Marroun HE, Tiemeier H, Steegers E, Jaddoe V, Hofman A, Verhulst F, et al. Intrauterine cannabis exposure affects fetal growth trajectories: the generation R study. *J Am Acad Child Adolesc Psychiatry* 2009; **48**: 1173–81.
- 56 Volkow N, Baler R, Compton W, Weiss S. Adverse health effects of marijuana use. *N Engl J Med* 2014; **370**: 2219–27.
- 57 Knight M, Bunch K, Tuffnell D, Shakespeare J, Kotnis R, Kenyon S, et al. (eds). *Saving Lives, Improving Mothers' Care: Lessons Learned to Inform Future Maternity Care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2016–2018*. MBRRACE-UK, 2020 (<https://www.birthingpartners.org.uk/resources/244-mbrance-uk-saving-lives-improving-mothers-care-2020>).
- 58 Navarrete F, García-Gutiérrez MS, Gasparyan A, Austrich-Olivares A, Femenía T, Manzanares J. Cannabis use in pregnant and breastfeeding women: behavioral and neurobiological consequences. *Front Psychiatry* 2020; **11**: 586447.
- 59 Gunn J, Rosales C, Center K, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. *BMJ Open* 2016; **6**(4): e009986.
- 60 Warshak C, Regan J, Moore B, Magner K, Kritzer S, Van Hook J. Association between marijuana use and adverse obstetrical and neonatal outcomes. *J Perinatol* 2015; **35**: 991–5.
- 61 Ayonrinde OT, Ayonrinde OA, Van Rooyen D, Tait R, Dunn M, Mehta S, et al. Association between gestational cannabis exposure and maternal, perinatal, placental, and childhood outcomes. *J Dev Orig Health Dis* 2021; **12**: 694–703.
- 62 Crume TL, Juhl AL, Brooks-Russell A, Hall KE, Wymore E, Borgelt LM. Cannabis use during the perinatal period in a state with legalized recreational and medical marijuana: the association between maternal characteristics, breastfeeding patterns, and neonatal outcomes. *J Pediatr* 2018; **197**: 90–6.
- 63 Corsi D, Walsh L, Weiss D, Hsu H, El-Chaar D, Hawken S, et al. Association between self-reported prenatal Cannabis use and maternal, perinatal, and neonatal outcomes. *JAMA* 2019; **322**: 145–52.
- 64 Moss MJ, Bushlin I, Kazmierczak S, Koop D, Hendrickson RG, Zuckerman KE, et al. Cannabis use and measurement of cannabinoids in plasma and breast milk of breastfeeding mothers. *Pediatr Res* [Epub ahead of print] 19 Jan 2021. Available from: <https://doi.org/10.1038/s41390-020-01332-2>.
- 65 Bertrand KA, Hanan NJ, Honerkamp-Smith G, Best BM, Chambers CD. Marijuana use by breastfeeding mothers and cannabinoid concentrations in breast milk. *Pediatrics* 2018; **142**(3): e20181076.
- 66 Baker T, Datta P, Rewers-Felkins K, Thompson H, Kallem RR, Hale TW. Transfer of inhaled cannabis into human breast milk. *Obstet Gynecol* 2018; **131**: 783–8.
- 67 Astley SJ, Little RE. Maternal marijuana use during lactation and infant development at one year. *Neurotoxicol Teratol* 1990; **12**: 161–8.
- 68 Marchetti D, Di Masi G, Cittadini F, La Monaca G, De Giovanni N. Placenta as alternative specimen to detect in utero cannabis exposure: a systematic review of the literature. *Reprod Toxicol* 2017; **17**: 250–8.
- 69 Ordean A, Kim G. Cannabis use during lactation: literature review and clinical recommendations. *J Obstet Gynaecol Can* 2020; **42**: 1248–53.
- 70 Frank D, Rose-Jacobs R, Crooks D, Cabral HJ, Gerteis J, Hacker KA, et al. Adolescent initiation of licit and illicit substance use: impact

of intrauterine exposures and post-natal exposure to violence. *Neurotoxicol Teratol* 2011; **33**: 100–9.

- 71 Paul SE, Hatoum AS, Fine JD, Johnson EC, Hansen I, Karcher NR, et al. Associations between prenatal cannabis exposure and childhood outcomes: results from the ABCD study. *JAMA Psychiatry* 2021; **78**: 64–76.
- 72 Marangoni C, Hernandez M, Faedda GL. The role of environmental exposures as risk factors for bipolar disorder: a systematic review of longitudinal studies. *J Affect Disord* 2016; **193**: 165–74.
- 73 Warner T, Roussos-Ross D, Behnke M. It's not your mother's marijuana: effects on maternal-fetal health and the developing child. *Clin Perinatol* 2014; **41**: 877–94.
- 74 Reid H MO, Lysenko-Martin MR, Snowden TM, Christie BR, Thomas JD. A systematic review of the effects of perinatal alcohol exposure and perinatal marijuana exposure on adult neurogenesis in the dentate Gyrus. *Alcohol Clin Exp Res* 2020; **44**: 1164–74.
- 75 Public Health England. *Safeguarding and Promoting the Welfare of Children Affected by Parental Alcohol and Drug Use: A Guide for Local Authorities*. Public Health England, 2018.
- 76 Cleaver H, Unell I, Aldgate J. *Children's Needs – Parenting Capacity. Child Abuse: Parental Mental Illness, Learning Disability, Substance Misuse, and Domestic Violence* (2nd edn). TSO (The Stationery Office), 2011.
- 77 Forray A, Merry B, Lin H, Prah Ruger J, Yonkers K. Perinatal substance use: a prospective evaluation of abstinence and relapse. *Drug Alcohol Depend* 2015; **150**: 147–55.
- 78 Massey SH, Lieberman DZ, Reiss D, Leve LD, Shaw DS, Neiderhiser JM. Association of clinical characteristics and cessation of tobacco, alcohol, and illicit drug use during pregnancy. *Am J Addict* 2011; **20**: 143–50.
- 79 Mead A. The legal status of cannabis (marijuana) and cannabidiol (CBD) under US law. *Epilepsy Behav* 2017; **70**: 288–91.
- 80 Glickman A, Sisti D. Prescribing medical cannabis: ethical considerations for primary care providers. *J Med Ethics* 2020; **46**: 227–30.
- 81 National Institute on Drug Abuse. *NIDA's Role in Providing Marijuana for Research*. NIDA, 2019 (<https://www.drugabuse.gov/drugs-abuse/marijuana/nidas-role-in-providing-marijuana-research> [cited 6 Nov 2019]).
- 82 Lambert B, Scheiner M, Campbell D. Ethical issues and addiction. *J Addict Dis* 2010; **29**: 164–74.
- 83 Kluge EH. When Caesarean section operations imposed by a court are justified. *J Med Ethics* 1988; **14**: 206–11.
- 84 Keyserlingk EW. *The Unborn Child's Right to Prenatal Care: A Comparative Law Perspective*. Quebec Research Centre of Private & Comparative Law, 1984.
- 85 Bewley S. Restricting the freedom of pregnant women. In *Ethical Issues in Maternal-Fetal Medicine* (ed D Dickenson): 131–46. Cambridge University Press, 2002.
- 86 Hui K, Angelotta C, Fisher CE. Criminalizing substance use in pregnancy: misplaced priorities. *Addiction* 2017; **112**: 1123–5.
- 87 Hulsey T. Prenatal drug use: the ethics of testing and incarcerating pregnant women. *Newborn Infant Nurs Rev* 2005; **5**: 93–6.
- 88 Walsh C. Psychedelics and cognitive liberty: reimagining drug policy through the prism of human rights. *Int J Drug Policy* 2016; **29**: 80–7.
- 89 Stafford N. Using words: the harm reduction conception of drug use and drug users. *Int J Drug Policy* 2007; **10**: 88–91.
- 90 Tammi T, Hurme T. How the harm reduction movement contrasts itself against punitive prohibition. *Int J Drug Policy* 2007; **18**: 84–7.
- 91 Philpot LM, Ebbert JO, Hurt RT. A survey of the attitudes, beliefs and knowledge about medical cannabis among primary care providers. *BMC Fam Pract* 2019; **20**(1): 17.
- 92 Holland CL, Nkumsah MA, Morrison P, Tarr JA, Rubio D, Rodriguez KL, et al. "Anything above marijuana takes priority": Obstetric providers' attitudes and counseling strategies regarding perinatal marijuana use. *Patient Educ Couns* 2016; **99**: 1446–51.
- 93 Berthelot N, Garon-Bissonnette J, Drouin-Maziade C, Duguay G, Milot T, Lemieux R, et al. Parental Cannabis use: contradictory discourses in the media, government publications, and the scientific literature. *J Am Acad Child Adolesc Psychiatry* 2020; **59**: 333–5.
- 94 Day E, George S. Management of drug misuse in pregnancy. *Adv Psychiatr Treat* 2005; **11**: 253–61.
- 95 Center for Substance Abuse Treatment. *Brief Interventions and Brief Therapies for Substance Abuse (Treatment Improvement Protocol (TIP) Series, No. 34)*. Substance Abuse and Mental Health Services Administration (US), 1999 (<https://www.ncbi.nlm.nih.gov/books/NBK64942/>).
- 96 Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. *Cochrane Database Syst Rev*; **2016**(5): CD005336.
- 97 Budney A, Hughes J. The cannabis withdrawal syndrome. *Curr Opin Psychiatry* 2006; **19**: 233–8.
- 98 American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders* (5th edn) (DSM-5). American Psychiatric Publishing, 2013.
- 99 Anderson M, Elk R, Andres R. Social, ethical and practical aspects of perinatal substance use. *J Subst Abuse Treat* 1997; **14**: 481–6.
- 100 Wilson C, Finch E, Kerr C, Shakespeare J. Alcohol, smoking, and other substance use in the perinatal period. *BMJ* 2020; **369**: m1627.
- 101 Young-Wolff K, Sarovar V, Tucker L, Goler N, Conway A, Weisner C, et al. Validity of self-reported cannabis use among pregnant females in northern California. *J Addict Med* 2020; **14**: 287–92.
- 102 García-Serra J, Ramis J, Simó S, Joya X, Pichini S, Vall O, et al. Alternative biological materials to detect prenatal exposure to drugs of abuse in the third trimester of pregnancy. *An Pediatr (Barc)* 2012; **77**: 323–8.
- 103 García-Algar O, Vall Combelles O, Puig Sola C, Mur Sierra A, Scaravelli G, Pacifici R, et al. Prenatal exposure to drugs of abuse using meconium analysis in a low socioeconomic population in Barcelona. *An Pediatr (Barc)* 2009; **70**: 151–8.
- 104 Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol adverse effects and toxicity. *Curr Neuropharmacol* 2019; **17**: 974–89.
- 105 National Institute for Health and Care Excellence. *Cannabis-Based Medicinal Products (NICE guideline NG144)*. NICE, 2019.
- 106 Ryan SA. A modern conundrum for the pediatrician: the safety of breast milk and the cannabis-using mother. *Pediatrics* 2018; **142**(3): e20181921.
- 107 Graves L. Cannabis and breastfeeding. *Paediatr Child Health* 2020; **25** (suppl.1): S26–8.
- 108 Davis E, Lee T, Weber JT, Bugden S. Cannabis use in pregnancy and breastfeeding: the pharmacist's role. *Can Pharm J* 2020; **153**: 95–100.
- 109 Skelton KR, Benjamin-Neelon SE, Young-Wolff KC. Management of cannabis use in breastfeeding women: the untapped potential of international board certified lactation consultants. *Breastfeed Med* 2020; **15**: 117–20.
- 110 Han B, Compton WM, Blanco C, Jones CM. Trends in and correlates of medical marijuana use among adults in the United States. *Drug Alcohol Depend* 2018; **186**: 120–9.